The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 19, 2021

Filed:

Feb. 17, 2016
Applicant:

Hanmi Pharm. Co., Ltd., Hwaseong-si, KR;

Inventors:

Yong Ho Heo, Hwaseong-si, KR;

Jong Soo Lee, Hwaseong-si, KR;

Sung Hee Park, Hwaseong-si, KR;

Dae Jin Kim, Hwaseong-si, KR;

Sung Youb Jung, Hwaseong-si, KR;

Se Chang Kwon, Hwaseong-si, KR;

Assignee:

HANMI PHARM. CO., LTD., Hwaseong-si, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/28 (2006.01); A61K 47/68 (2017.01); C07K 14/62 (2006.01); A61K 47/50 (2017.01); A61K 47/60 (2017.01); A61P 3/10 (2006.01); C12N 15/67 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6811 (2017.08); A61K 38/28 (2013.01); A61K 47/50 (2017.08); A61K 47/60 (2017.08); A61P 3/10 (2018.01); C07K 14/62 (2013.01); C12N 15/67 (2013.01); A61K 38/00 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/528 (2013.01); C07K 2317/53 (2013.01); C07K 2319/30 (2013.01); C12N 2840/203 (2013.01);
Abstract

The present invention relates to insulin and/or an insulin analogue conjugate, and a use thereof, wherein the insulin and/or insulin analogue have improved in vivo durability and stability by linking the same with an Fc region of immunoglobulin. The insulin and/or an insulin analogue conjugate of the present invention show an in vivo activity similar to that of insulin. In addition, the insulin and/or insulin analogue conjugate of the present invention are long-acting formulations of insulin and/or the analogue thereof, in which serum half-life is remarkably increased, and therefore, the present invention provides remarkable insulin and/or an insulin analogue conjugate, which do not induce hypoglycemia, a drawback of insulin treatment.


Find Patent Forward Citations

Loading…